BridgeBio Oncology Therapeutics Inc.
BBOTHealthcare|Biotechnology|US
$2.04
-0.13 (-5.99%)
DCF Value
$11.88
Tangible Book / Share
$4036.18
Cash / Share
$2819.48
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06917079 BBO-11818 in Adult Subjects With KRAS Mutant Cancer | Non-Small Cell Lung Cancer, NSCLC | P1 | Recruiting | 665 | Open-label | BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel |
| NCT06343402 Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | P1 | Recruiting | 350 | Open-label | BBO-8520, Pembrolizumab, BBO-10203 |
| NCT06625775 Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Solid Tumor, Adult, Metastatic Breast Cancer | P1 | Recruiting | 392 | Open-label | BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX, Bevacizumab |